32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Towards precision medicine for AML

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references139

          • Record: found
          • Abstract: not found
          • Article: not found

          The Hallmarks of Cancer

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

            The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

              The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Nature Reviews Clinical Oncology
                Nat Rev Clin Oncol
                Springer Science and Business Media LLC
                1759-4774
                1759-4782
                May 18 2021
                Article
                10.1038/s41571-021-00509-w
                fe109108-02c4-4e87-a4f8-368da64912c1
                © 2021

                https://www.springer.com/tdm

                https://www.springer.com/tdm

                History

                Comments

                Comment on this article